Videos

Paul Swiecicki, MD, discusses results from cohort 5 of the OrigAMI-4 trial evaluating subcutaneous amivantamab plus pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma, highlighting...

Andrea Necchi, MD, discusses final results from the phase 3 ENERGIZE trial evaluating perioperative nivolumab plus gemcitabine and cisplatin in muscle-invasive bladder cancer, highlighting the absence of significant event-free survival or...

Kohei Shitara, MD, discusses results from the phase 3 G-HOPE-001 trial evaluating arcotatug tavatecan versus chemotherapy in previously treated CLDN18.2-positive advanced gastric and gastroesophageal junction cancer, highlighting significant...

Kohei Shitara, MD, discusses updated results from the phase 3 HERIZON-GEA-01 trial evaluating zanidatamab plus chemotherapy, with or without tislelizumab, in HER2-positive gastroesophageal cancer, highlighting improved overall survival with...

Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...

Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...

Vivek Subbiah, MD, discusses advances in tumor-agnostic precision oncology, highlighting comprehensive genomic profiling, actionable molecular alterations, and biomarker-directed therapies across cancer types, as well as the importance of...

Joseph Mikhael, MD, discusses individualized treatment strategies for older and frail patients with multiple myeloma, highlighting comprehensive frailty assessment, dose optimization of lenalidomide, bortezomib, and dexamethasone, and...

Daniel King, MD, PhD, reviews the clinical decision-making behind the management of a patient with suspected metastatic pancreatic cancer, highlighting the role of molecular profiling in guiding treatment selection and clinical trial...

In this case-based discussion, experts examine the phase 3 RASolute 302 efficacy and safety data for daraxonrasib, an FDA-approved RAS inhibitor for metastatic pancreatic adenocarcinoma (mPDAC). The panelists discuss how to interpret the...